Pages

Showing posts with label genome editing. Show all posts
Showing posts with label genome editing. Show all posts

Thursday, November 19, 2020

Human germline editing: Legal-ethical guidelines for South Africa [Scholarly Article - South African Journal of Science, 2020]

Title:
Human germline editing: Legal-ethical guidelines for South Africa
 
Authors:
Donrich Thaldar, Marietjie Botes, Bonginkosi Shozi, Beverley Townsend & Julian Kinderlerer
[All from the University of KwaZulu-Natal, South Africa]

Published:
South African Journal of Science, Volume 116, Number 10 (2020)

Abstract:
Human germline editing holds much promise for improving people’s lives, but at the same time this novel biotechnology raises ethical and legal questions. The South African ethics regulatory environment is problematic, as it prohibits all research on, and the clinical application of, human germline editing. By contrast, the South African legal regulatory environment allows a regulatory path that would, in principle, permit research on human germline editing. However, the legal regulation of the clinical application of human germline editing is uncertain. As such, the current ethical and legal positions in South Africa are in need of reform. Five guiding principles – aligned with the values of the Constitution – are proposed to guide ethical and legal policy reform regarding human germline editing in South Africa: (1) Given its potential to improve the lives of the people of South Africa, human germline editing should be regulated, not banned. (2) Human germline editing clinical applications should only be made accessible to the public if they are proven to be safe and effective. (3) Non-therapeutic human germline editing may be permissible, and should be regulated in the same way as therapeutic human germline editing. (4) The decision on whether to use germline gene editing on a prospective child, should, subject to Principle 2, be left to the prospective parents. (5) Concerns about exacerbating social inequalities should be addressed by measures to increase access. In conclusion, recommendations are made to policymakers and scientists contemplating research in this field.

Thursday, June 25, 2020

Peter Diamandis (tech blog, 21 June 2020) - Longevity & Vitality - A Renaissance of Drugs and Genomics

Title:
Longevity & Vitality - A Renaissance of Drugs and Genomics

Blog owner post:
Peter Diamandis

Published:
tech blog, 21 June 2020
https://www.diamandis.com/blog/longevity-drugs-and-genomics

From the blog post:
The causes of aging are extremely complex and unclear.

But with longevity clinical trials increasing 3.5X, from 73 in 2012 to over 258 in 2019, more answers — and questions — are emerging than ever before.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

In this blog, I will explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.